Vagal Nerve Stimulation in Epilepsy: Experiences of Participants with Cognitive Deficits
Received 10 December 2019
Accepted for publication 17 April 2020
Published 8 May 2020 Volume 2020:16 Pages 1181—1188
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Roger Pinder
Eva Pipan,1 Alexandros Apostolou,2 Maria Bograkou,2 Petra Brooks,2 Patrick Vigren,2 Helena Gauffin2
1University Medical Centre Ljubljana, Ljubljana, Slovenia; 2Department of Neurology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
Correspondence: Eva Pipan
University Medical Centre Ljubljana, University of Ljubljana, Ljubljana, Slovenia
Introduction: The purpose of this study was to examine patients’ experiences of vagal nerve stimulation (VNS) with a special interest in patients with cognitive deficit (CD).
Materials and Methods: An open, retrospective study was conducted on 82 patients with pharmacoresistant epilepsy, who were treated with VNS for at least 10 months. Based on the inability to live independently, they were divided into two groups: patients with cognitive deficit (CD group) and patients without cognitive deficit (non-CD group). A specially designed questionnaire was used for semi-structured interviews about patients’ experiences of VNS treatment.
Results: Approximately one-third described a continuous reduction of seizure frequency of 50% or more and were regarded as responders. Fewer subjects in the CD group were responders than in the non-CD group. Approximately one-third of all subjects had no positive effect of VNS treatment. More CD patients described additional improvements and the most common were milder seizures and improved alertness. The most commonly reported adverse effect was hoarseness.
Discussion: VNS treatment in patients without CD had better effect on seizure frequency reduction than in patients with CD, but many patients with CD reported other benefits from the treatment.
Conclusion: Non-CD patients had higher seizure frequency reduction than CD patients during VNS treatment, but many CD patients described other benefits.
Keywords: epilepsy, vagus nerve stimulation, cognitive deficit, cognitive dysfunction
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]